{"id":1177,"date":"2018-09-23T11:34:04","date_gmt":"2018-09-23T11:34:04","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1177"},"modified":"2026-02-24T15:40:15","modified_gmt":"2026-02-24T15:40:15","slug":"leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/","title":{"rendered":"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam)"},"content":{"rendered":"

Although new molecular technologies and computational prediction tools offer wide-raging opportunities in genetic diagnostic settings, they have many limitations. We contextualize these limitations by investigating incorrect variant detection in genomic regions of high sequence similarities and from inappropriate computational analysis. For instance, we observed a 5% false positive rate in MYH7<\/em> variant detection due to high sequence similarity to MYH6<\/em>. Additionally, using inappropriate computational files during analysis (eg. annotation and default files) significantly increased the risk of incorrect variant detection for certain genes. This study shows that molecular technologies have limitations that need to be addressed to avoid inaccurate diagnoses. (https:\/\/jmg.bmj.com\/content\/early\/2018\/09\/21\/jmedgenet-2018-105443<\/a> )<\/p>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Although new molecular technologies and computational prediction tools offer wide-raging opportunities in genetic diagnostic settings, they have many limitations. We contextualize these limitations by investigating incorrect variant detection in genomic regions of high sequence similarities and from inappropriate computational analysis. For instance, we observed a 5% false positive rate in MYH7 variant detection due to […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1177","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nLeveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Although new molecular technologies and computational prediction tools offer wide-raging opportunities in genetic diagnostic settings, they have many limitations. We contextualize these limitations by investigating incorrect variant detection in genomic regions of high sequence similarities and from inappropriate computational analysis. For instance, we observed a 5% false positive rate in MYH7 variant detection due to [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-23T11:34:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T15:40:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2018\/09\/Group-Picture.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"6000\" \/>\n\t<meta property=\"og:image:height\" content=\"3900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam)\",\"datePublished\":\"2018-09-23T11:34:04+00:00\",\"dateModified\":\"2026-02-24T15:40:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/\"},\"wordCount\":135,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2018\\\/09\\\/Group-Picture-300x195.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/\",\"name\":\"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2018\\\/09\\\/Group-Picture-300x195.jpg\",\"datePublished\":\"2018-09-23T11:34:04+00:00\",\"dateModified\":\"2026-02-24T15:40:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2018\\\/09\\\/Group-Picture.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2018\\\/09\\\/Group-Picture.jpg\",\"width\":6000,\"height\":3900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2018\\\/09\\\/23\\\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/","og_locale":"en_US","og_type":"article","og_title":"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam) - JMG Contact blog","og_description":"Although new molecular technologies and computational prediction tools offer wide-raging opportunities in genetic diagnostic settings, they have many limitations. We contextualize these limitations by investigating incorrect variant detection in genomic regions of high sequence similarities and from inappropriate computational analysis. For instance, we observed a 5% false positive rate in MYH7 variant detection due to [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/","og_site_name":"JMG Contact blog","article_published_time":"2018-09-23T11:34:04+00:00","article_modified_time":"2026-02-24T15:40:15+00:00","og_image":[{"width":6000,"height":3900,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2018\/09\/Group-Picture.jpg","type":"image\/jpeg"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam)","datePublished":"2018-09-23T11:34:04+00:00","dateModified":"2026-02-24T15:40:15+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/"},"wordCount":135,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2018\/09\/Group-Picture-300x195.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/","url":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/","name":"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2018\/09\/Group-Picture-300x195.jpg","datePublished":"2018-09-23T11:34:04+00:00","dateModified":"2026-02-24T15:40:15+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2018\/09\/Group-Picture.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2018\/09\/Group-Picture.jpg","width":6000,"height":3900},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2018\/09\/23\/leveraging-the-power-of-new-molecular-technologies-in-the-clinical-setting-requires-unprecedented-awareness-of-limitations-and-drawbacks-experience-of-one-diagnostic-laboratory\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Leveraging the Power of New Molecular Technologies in the Clinical Setting Requires Unprecedented Awareness of Limitations and Drawbacks: Experience of One Diagnostic Laboratory (Contributed by Dr. Landry Nfonsam)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1177"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1177\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}